Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 12,000 shares at $23.66 ($284K) on 2023-08-08, disclosed to the SEC on 2023-08-09.
Scheduled sale ($284k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2026-01-15 | $51K | — | Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-23 | $240K | — | Filing → |